TABLE 8.
Likelihood of achieving the designated re-epithelialization levels within the observation period by subgroup stratum.
| Re-ep*-level | Insulin | No insulin | Total | ||
|---|---|---|---|---|---|
| EPO + I | Placebo + I | EPO | Placebo | ||
| %, (no) | (n = 17) | (n = 19) | (n = 24) | (n = 18) | (n = 78) |
| 50% | 100% (17) | 95% (18) | 96% (23) | 94% (17) | 96% (75) |
| 75% | 82% (14) | 84% (16) | 79% (19) | 94% (17) | 85% (66) |
| 100% | 6% (1) | 16% (3) | 42% (10) | 44% (8) | 28% (22) |
* re-ep, re-epithelialization; 36 of 84 patients received insulin, insulin group: EPO + insulin (E + I), placebo + insulin (P + I), no insulin group: EPO (E), placebo (P).